Other substances

Bafilomycin A1

A macrolide V-ATPase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Bafilomycin A1 on PubChem

Structure image - Bafilomycin A1

C[C@H]1C/C(=C/C=C/[C@@H]([C@H](OC(=O)/C(=C/C(=C/[C@H]([C@H]1O)C)/C)/OC)[C@@H](C)[C@H]([C@H](C)[C@]2(C[C@H]([C@@H]([C@H](O2)C(C)C)C)O)O)O)OC)/C

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Small molecule	in silico	42.78		Apr/30/2020
Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2 Membrane protein Small molecule In silico	in silico	3.00	Predicted to bind SARS-CoV-2 Membrane protein.	Mar/05/2021

AI-suggested references

Link	Publication date
Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2.	Jun/11/2021
Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays	Mar/16/2021
Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice	Feb/27/2021